RTSN
Neutral signalScored 2026-10-25 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Retension Pharmaceuticals Inc.
- Nom
- Retension Pharmaceuticals Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Pharmaceuticals
- Bourse
- NASDAQ
- Capitalisation
- $58.2M
- Employés
- 12
- PDG
- Eric L. Keller
- Site web
- http://www.retensionpharmaceuticals.com
- Marché
- —
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 20 800 titres (~249 600,00 $ US)
- Insiders
- Keller Eric L.
- Total bought
-
$249,600
Avg buy (VWAP, 90d window) $12.00 vs last close $14.68 (+22.3%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-10-13
- Liquidity
- Thin $2,744,115/day · 12d vol
- Last synced
-
2026-10-26 21:10:55
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-13 | Keller Eric L. | Buy · P | 20,800 | $12.00 | $249,600 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-25 Drivers: fundamentals. Moteurs : fondamentaux.
RTSN shows a single post-IPO insider purchase that signals some management confidence, but the complete absence of financial data makes it impossible to assess liquidity, solvency, or operational viability.
The first sentence of the analysis written for RTSN on 2026-10-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Unavailable or mixed. Weekly bias is flat
- Financial indicators Unavailable or mixed. No liquidity or margin figures stored
Suggested stop 11.40, 1.5 ATR under the last close(22.3% under the last close). Research, not advice. Not an order.
Market snapshot
Financial ratios
No ratio data synced.
Key metrics
No metrics data synced.
Employee count
No employee-count data synced.
Peer market caps
No peer data synced.